Cost-effectiveness of integrated prevention for late-life depressive symptoms: Real-world findings from a large-scale pragmatic trial (“JoyAge”).
Key claim: A community-based stepped-care prevention program for late-life depression is highly cost-effective compared to usual care, generating approximately 32 depression-free days at an incremental cost of $251 per person.
Abstract
BACKGROUND: Integrated prevention, including stepped-care and task-sharing, is a theoretically resource-efficient approach to address late-life depression. Real-world evidence from large-scale community-based prevention programmes is lacking. We conducted a cost-effectiveness study embedded in a pragmatic non-randomised controlled trial to evaluate JoyAge, an integrated prevention programme for late-life depression, which has been shown to reduce loneliness, anxiety and depressive symptoms compared with routine care. METHODS: We compared an intention-to-treat sample of people receiving JoyAge (n = 2975) with people receiving usual care (n = 441) for incremental depression-free days (DFDs), quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness at 1 year. Using a two-part model to estimate incremental costs, nonparametric bootstrap was used to simulate 5000 incremental cost-effectiveness ratios. Cost-effectiveness probability was evaluated against US, UK, and WHO willingness-to-pay thresholds for QALY gain. Subgroup analyses were performed by baseline depressive symptom/prevention levels. RESULTS: At an incremental cost of US$251, JoyAge has an incremental effectiveness of 31.86 DFDs and 0.01 QALYs. Incremental cost-effectiveness ratios were US$9 per DFD (95% CI: -9, 27) and US$20,063 per QALY (95% CI: -23,527, 82,287). JoyAge has a 95% likelihood of being cost-effective at willingness-to-pay thresholds of US$24 per DFD, and is 99.9% likely to be cost-effective per QALY using the WHO threshold. Selective prevention dominated in gaining DFDs and QALYs. Indicated prevention and treatment were more effective but more expensive than care-as-usual. CONCLUSIONS: JoyAge presented good value for money compared with care-as-usual. Decision-makers should consider integrated preventive programmes for late-life depression in rapidly ageing and lower-resource societies.
Why this matters
[human-observational] JoyAge adds a real-world economic evaluation of integrated late-life depression prevention, expressing benefit as additional depression-free days rather than an acute stress biomarker or an inferred aging effect. [human-observational] The reported costs and depression outcomes concern the bundled stepped-care program; they do not establish loneliness-specific cost-effectiveness, the independent contribution of social connection, or longer life, and randomization is not established in the supplied finding.